Literature DB >> 2317956

Reduction of metastasis in a murine mammary tumour model by heparin and polyinosinic-polycytidylic acid.

A E Lee1, L A Rogers, J M Longcroft, R E Jeffery.   

Abstract

A murine mammary tumour model has been used to test the efficacy of a combination of heparin and the interferon inducer, poly I:C on spontaneous metastasis from a s.c. primary tumour and on experimental metastasis following i.v. injection of tumour cells. This treatment has no effect on the growth of primary tumours, but lung metastases arising from these tumours were reduced. When tumour cells were injected i.v. the number of lung colonies was significantly reduced and survival time extended. Short-term treatment did not prevent the subsequent growth of extravasated, but dormant tumour cells, although mice treated for 8 or 12 weeks survived at least 6 months without any sign of lung colonies. Several mechanisms may contribute to the overall effect of this treatment; a reduction in the mitotic indices of lung colonies (observed in poly I:C treated mice) and also NK cells appeared to be important for the effectiveness of poly I:C since the reduction in experimental metastasis was abrogated by concomitant treatment with anti-asialo GM1 serum.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2317956     DOI: 10.1007/bf00117789

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  22 in total

1.  Action of recombinant alpha interferon against experimental and spontaneous metastases in a murine model.

Authors:  P Ramani; F R Balkwill
Journal:  Int J Cancer       Date:  1989-01-15       Impact factor: 7.396

Review 2.  Interaction of the hemostatic and immune systems in the metastatic spread of tumor cells.

Authors:  G J Gasic; G P Tuszynski; E Gorelik
Journal:  Int Rev Exp Pathol       Date:  1986

3.  Reinfection of virus free mice with mouse mammary tumour virus.

Authors:  A E Lee; L A Rogers; S Topps; K Wallace
Journal:  Lab Anim       Date:  1989-04       Impact factor: 2.471

4.  Warfarin inhibits both procoagulant activity and metastatic capacity of Lewis lung carcinoma cells. Role of vitamin K deficiency.

Authors:  M Colucci; F Delaini; G de Bellis Vitti; D Locati; A Poggi; N Semeraro; M B Donati
Journal:  Biochem Pharmacol       Date:  1983-06-01       Impact factor: 5.858

5.  Inhibition of tumor cell metastasis by modulation of the vascular prostacyclin/thromboxane A2 system.

Authors:  K V Honn
Journal:  Clin Exp Metastasis       Date:  1983 Apr-Jun       Impact factor: 5.150

6.  Immunomodulatory effects in mice of polyinosinic-polycytidylic acid complexed with poly-L-lysine and carboxymethylcellulose.

Authors:  J E Talmadge; J Adams; H Phillips; M Collins; B Lenz; M Schneider; E Schlick; R Ruffmann; R H Wiltrout; M A Chirigos
Journal:  Cancer Res       Date:  1985-03       Impact factor: 12.701

7.  Inhibitory effect of interferon on the growth of spontaneous mammary tumors in mice.

Authors:  E De Clercq; Z X Zhang; K Huygen; R Leyten
Journal:  J Natl Cancer Inst       Date:  1982-09       Impact factor: 13.506

8.  In vivo augmentation of rat lung natural killer cell activity and inhibition of experimental metastases by double-stranded polynucleotides.

Authors:  D Nolibe; E Aumaitre; M N Thang
Journal:  Cancer Res       Date:  1985-10       Impact factor: 12.701

9.  Role of natural killer cells in the destruction of circulating tumor emboli.

Authors:  N Hanna; I J Fidler
Journal:  J Natl Cancer Inst       Date:  1980-10       Impact factor: 13.506

10.  Warfarin inhibits metastasis of Mtln3 rat mammary carcinoma without affecting primary tumour growth.

Authors:  P McCulloch; W D George
Journal:  Br J Cancer       Date:  1989-02       Impact factor: 7.640

View more
  7 in total

1.  ICAM-1 mediated peritoneal carcinomatosis, a target for therapeutic intervention.

Authors:  Nawar A Alkhamesi; Paul Ziprin; Katherine Pfistermuller; David H Peck; Ara W Darzi
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

Review 2.  Impact of venous thromboembolism and anticoagulation on cancer and cancer survival.

Authors:  Nicole M Kuderer; Thomas L Ortel; Charles W Francis
Journal:  J Clin Oncol       Date:  2009-09-08       Impact factor: 44.544

3.  Identification of a polyI:C-inducible membrane protein that participates in dendritic cell-mediated natural killer cell activation.

Authors:  Takashi Ebihara; Masahiro Azuma; Hiroyuki Oshiumi; Jun Kasamatsu; Kazuya Iwabuchi; Kenji Matsumoto; Hirohisa Saito; Tadatsugu Taniguchi; Misako Matsumoto; Tsukasa Seya
Journal:  J Exp Med       Date:  2010-11-08       Impact factor: 14.307

4.  Anticoagulation inhibits tumor cell-mediated release of platelet angiogenic proteins and diminishes platelet angiogenic response.

Authors:  Elisabeth M Battinelli; Beth A Markens; Rajesh A Kulenthirarajan; Kellie R Machlus; Robert Flaumenhaft; Joseph E Italiano
Journal:  Blood       Date:  2013-09-24       Impact factor: 22.113

5.  Clinical use of the low-molecular-weight heparins in cancer patients: focus on the improved patient outcomes.

Authors:  Bo H Chao; Lisa Lepeak; Ticiana Leal; H Ian Robins
Journal:  Thrombosis       Date:  2011-04-12

6.  The Antitumor Effect of Heparin is not Mediated by Direct NK Cell Activation.

Authors:  Gustavo R Rossi; Jenifer P Gonçalves; Timothy McCulloch; Rebecca B Delconte; Robert J Hennessy; Nicholas D Huntington; Edvaldo S Trindade; Fernando Souza-Fonseca-Guimaraes
Journal:  J Clin Med       Date:  2020-08-18       Impact factor: 4.241

Review 7.  Harnessing the immune system in the battle against breast cancer.

Authors:  Elizabeth S Nakasone; Sara A Hurvitz; Kelly E McCann
Journal:  Drugs Context       Date:  2018-02-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.